or Try an Advanced Search...

    Intravitreal Administration Stocks List

    Symbol Grade Name % Change
    ANNX F Annexon, Inc. -0.58
    APLS D Apellis Pharmaceuticals, Inc. 10.88
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Clinical Medicine Complement System Eye Medicine Acquired Hemolytic Anemia Antibody Autoimmune And Inflammatory Disease Autoimmunity Biomarkers Biotechnology Chronic Obstructive Pulmonary Disease Copd Degenerative Disease Hemoglobin Hemoglobinuria Immune System Immunology Inflammatory Diseases Macular Degeneration

    Related ETFs - A few ETFs which own one or more of the above listed Intravitreal Administration stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 1.04
    XBI D SPDR S&P Biotech ETF 1.02
    BBC F Virtus LifeSci Biotech Clinical Trials ETF 0.88
    LABU F Direxion Daily S&P Biotech Bull 3X Shares 0.68
    SBIO C ALPS Medical Breakthroughs ETF 0.4
    View all Intravitreal Administration ETFs...
    Compare ETFs
    Compare BBP to SBIO Compare XBI to LABU Compare XBI to SBIO

        Intravitreal Administration Stocks Recent News

        Date Stock Title
        Nov 21 APLS Apellis started at equal-weight at Morgan Stanley on geographic atrophy market
        Nov 19 ANNX The Dodgers’ World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Clinical Medicine Complement System Eye Medicine Acquired Hemolytic Anemia Antibody Autoimmune And Inflammatory Disease Autoimmunity Biomarkers Biotechnology Chronic Obstructive Pulmonary Disease Copd Degenerative Disease Hemoglobin Hemoglobinuria Immune System Immunology Inflammatory Diseases Macular Degeneration
        Intravitreal Administration

        Intravitreal administration is a method of delivering medication directly into the vitreous humor of the eye. This method is used to treat a variety of eye conditions, including age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. The medication is injected directly into the eye, bypassing the blood-retinal barrier and allowing for a higher concentration of the medication to reach the retina.

        Browse All Tags